Entity

Time filter

Source Type

Tres Cantos, Spain

Robinson D.S.,Imperial College London | Robinson D.S.,Laboratorios LETI SL
Journal of Allergy and Clinical Immunology | Year: 2010

Since the initial detection of TH2 cytokines in asthmatic airways, our understanding of the complexity of T-cell subtypes and flexibility and of the potential role of airway structural cells in the immunopathology of asthma has increased. Cytokines derived from airway epithelium, including IL-25, IL-33, and thymic stromal lymphopoietin, might be important drivers of T H2-type inflammation in asthma. The balance between effector T H2 cells and suppressive regulatory T cells is skewed toward a proinflammatory TH2 response in atopy and asthma, and there is much interest in how to redress this equilibrium. Novel T-cell subsets, including TH17, TH9, and TH22, have been described, although their role in asthma remains unclear. Other T cells, including natural killer T cells, γδ T cells, and CD8 T cells, have also been implicated in asthma, although their importance remains to be confirmed. Therapeutic strategies aimed at TH2 cytokines are beginning to bear fruit in patients with asthma, although like many biologic agents, these might need specific targeting at subgroups of patients. Strategies directed specifically at the T cells are currently being evaluated, including novel forms of allergen immunotherapy. T cells remain an exciting potential target for new treatments in patients with asthma. © 2010 American Academy of Allergy, Asthma & Immunology. Source


Pfaar O.,University of Mannheim | Robinson D.S.,Laboratorios LETI SL | Sager A.,LETI Pharma | Emuzyte R.,Vilnius University
Allergy: European Journal of Allergy and Clinical Immunology | Year: 2010

Background: Rhinoconjunctivitis because of tree pollen sensitization is common in Northern Europe. Specific subcutaneous immunotherapy (SCIT) is the only disease-modifying treatment, but unmodified allergen extracts carry a risk of allergic side-effects. Our objective was to examine efficacy and safety of a depigmented-polymerized mixed tree pollen extract. Methods: A double-blind, placebo-controlled trial of 184 tree pollen allergic adults was performed. SCIT consisted of four increasing doses at 7-day intervals, then maintenance injections every 6weeks for 18months. Primary outcome was combined symptom and medication score during the 2008 season. Secondary outcomes included analysis at different levels of pollen exposure and a responder analysis. Adverse events were classified using the EAACI scale. Birch pollen-specific IgE and IgG 4 were measured before and after treatment. Results: The combined symptom and medication score of actively treated patients was significantly lower than those on placebo (P<0.04). Increased efficacy was seen at high pollen exposure (median score 2.1 for active [IQR 0.7-3.4] vs 4.2 [IQR 2.4-5.3] for placebo for days with 500 or more pollen grains per m3, a 50% reduction, P<0.01). A modified responder analysis revealed 64% responders in the active and 32% in the placebo group (P<0.01). There were 17 systemic reactions. All were mild (grade 1 or 2) and required no treatment. Serum birch-specific IgG4 increased in the SCIT group (P<0.01). Conclusions: SCIT with depigmented-polymerized tree pollen extract was clinically effective and well tolerated. Responder analysis suggested that one-third of patients treated with immunotherapy may not respond. © 2010 John Wiley & Sons A/S. Source


Hoiby A.-S.,Sahlgrenska University Hospital | Strand V.,St Goran Hospital | Robinson D.S.,Laboratorios LETI SL | Sager A.,LETI Pharma | Rak S.,Sahlgrenska University Hospital
Clinical and Experimental Allergy | Year: 2010

Background Rhinoconjunctivitis due to birch pollen sensitization is common in Northern Europe. A depigmented polymerized birch pollen extract - Depigoid® has been developed for immunotherapy. Objective To evaluate its clinical efficacy, safety, and effects on immunological parameters. Methods Sixty-one patients aged 7-69 years were included in a randomized, double-blind, placebo-controlled trial of subcutaneous immunotherapy (SCIT) using depigmented polymerized birch pollen extract. SCIT consisted of four increasing doses at 7-day intervals, followed by maintenance injections of 500 DPP (corresponding to 30 μg Bet v1 before depigmentation) at 6-week intervals for 18 months. The primary outcome was the combined symptom and medication score during the 2006 birch pollen season. The frequency of peripheral blood mononuclear cells (PBMC)producing IL-4, IL-10, IL-12, and IL-13 was assessed in a subgroup of patients by ELISPOT assay. Results After 18 months of treatment, the median combined symptom and medication score (upper/lower quartile) of treated patients was significantly lower than those on placebo: 8.0 (5.8-10.3) and 12.6 (8.6-16.2), respectively (P=0.004). Systemic reactions occurred in 29 patients (12 active, 17 placebo), were grades 1 or 2, and none required specific treatment. After 18 months of treatment, mean serum concentrations of specific IgE increased significantly in both groups (P<0.0001) whereas serum concentrations of both specific IgG1 and IgG4 only increased significantly in the SCIT group (P=0.002) and not in the placebo group. The seasonal increase in numbers of IL-4- and IL-13-producing PBMC was blunted by immunotherapy. Conclusions SCIT with depigmented polymerized birch pollen extract significantly reduced symptom and medication scores when compared with the placebo, was well tolerated, and resulted in immunological changes comparable with those of native pollen extracts. © 2010 Blackwell Publishing Ltd. Source


Patent
Laboratorios Leti S.L. | Date: 2012-05-08

The invention provides a L19 source as a medicament, preferably for preventing or treating an inflammatory disorder in an individual.


It comprises a combination of glycerin, niacinamide, and an extract of

Discover hidden collaborations